During early CKD stages, rising EPO levels constitute a compensatory mechanism addressing hemoglobin decline from erythrocyte degradation
Mishriky BM, Cummings DM, Tanenberg RJ (2015) The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with type 2 diabetes: a systematic review and meta-analysis
A: Mounjaro is given as a once-weekly subcutaneous injection, starting at a low dose that may be increased based on individual tolerance and response
If CRP dropped meaningfully (e.g., from 2.5 to 1.0), the protocol is working at a systemic level
The most helpful way to look at it is as a medically guided tool that can make healthy changes more achievable, not unnecessary
It is FDA-approved for type 2 diabetes (Mounjaro), weight loss (Zepbound), and obstructive sleep apnea in adults with obesity